(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Must-See Public Parks from Around the Globe - 2Which camera do you believe is great for first-time clients? !
- 3Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- 4the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- 5Finding Ideal Date Spots for Two or three Encounters
- Improving as a Pioneer: Examples from My Vocation
- Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
- Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- JFK's granddaughter Tatiana Schlossberg reveals terminal cancer diagnosis
- Figure out How to Alter Your Volvo XC40 for Further developed Solace
- From Lounge chair to Money: Online Positions That Will Change Your Profession
- Well known SUVs With Low Energy Utilization In 2024 vote
- The Benefits of Rehearsing Careful Nurturing
